Scancell to focus on fundraising for Phase II trial of SCIB1

Clinical-stage pharma company Scancell Holdings says in 2017 it will focus on raising the funds necessary to commence a Phase II SCIB1 trial in combination with a checkpoint inhibitor.

The company is developing two distinct immunotherapy platforms, each with broad applications and targeting multi-billion dollar markets.

ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors.

Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers.

"2017 will concentrate on raising the necessary funds to enable the commencement of a Phase II SCIB1 trial in combination with a checkpoint inhibitor," said Scancell in a statement.

At 10:33 GMT, shares in AIM-quoted Scancell were flat at 14.62p each.